Skip to main content
Top
Published in: BMC Medical Imaging 1/2019

Open Access 01-12-2019 | Magnetic Resonance Imaging | Research article

Gadoxetate-enhanced dynamic contrast-enhanced MRI for evaluation of liver function and liver fibrosis in preclinical trials

Authors: Jimi Huh, Su Jung Ham, Young Chul Cho, Bumwoo Park, Bohyun Kim, Chul-Woong Woo, Yoonseok Choi, Dong-Cheol Woo, Kyung Won Kim

Published in: BMC Medical Imaging | Issue 1/2019

Login to get access

Abstract

Background

To facilitate translational drug development for liver fibrosis, preclinical trials need to be run in parallel with clinical research. Liver function estimation by gadoxetate-enhanced dynamic contrast-enhanced MRI (DCE-MRI) is being established in clinical research, but still rarely used in preclinical trials. We aimed to evaluate feasibility of DCE-MRI indices as translatable biomarkers in a liver fibrosis animal model.

Methods

Liver fibrosis was induced in Sprague-Dawley rats by thioacetamide (200 mg, 150 mg, and saline for the high-dose, low-dose, and control groups, respectively). Subsequently, DCE-MRI was performed to measure: relative liver enhancement at 3-min (RLE-3), RLE-15, initial area-under-the-curve until 3-min (iAUC-3), iAUC-15, and maximum-enhancement (Emax). The correlation coefficients between these MRI indices and the histologic collagen area, indocyanine green retention at 15-min (ICG-R15), and shear wave elastography (SWE) were calculated. Diagnostic performance to diagnose liver fibrosis was also evaluated by receiver-operating-characteristic (ROC) analysis.

Results

Animal model was successful in that the collagen area of the liver was the largest in the high-dose group, followed by the low-dose group and control group. The correlation between the DCE-MRI indices and collagen area was high for iAUC-15, Emax, iAUC-3, and RLE-3 but moderate for RLE-15 (r, − 0.81, − 0.81, − 0.78, − 0.80, and − 0.51, respectively). The DCE-MRI indices showed moderate correlation with ICG-R15: the highest for iAUC-15, followed by iAUC-3, RLE-3, Emax, and RLE-15 (r, − 0.65, − 0.63, − 0.62, − 0.58, and − 0.56, respectively). The correlation coefficients between DCE-MRI indices and SWE ranged from − 0.59 to − 0.28. The diagnostic accuracy of RLE-3, iAUC-3, iAUC-15, and Emax was 100% (AUROC 1.000), whereas those of RLE-15 and SWE were relatively low (AUROC 0.777, 0.848, respectively).

Conclusion

Among the gadoxetate-enhanced DCE-MRI indices, iAUC-15 and iAUC-3 might be bidirectional translatable biomarkers between preclinical and clinical research for evaluating histopathologic liver fibrosis and physiologic liver functions in a non-invasive manner.
Literature
1.
go back to reference Ramachandran P, Henderson NC. Antifibrotics in chronic liver disease: tractable targets and translational challenges. Lancet Gastroenterol Hepatol. 2016;1(4):328–40.PubMedCrossRef Ramachandran P, Henderson NC. Antifibrotics in chronic liver disease: tractable targets and translational challenges. Lancet Gastroenterol Hepatol. 2016;1(4):328–40.PubMedCrossRef
2.
go back to reference Van Beers BE, Pastor CM, Hussain HK. Primovist, Eovist: what to expect? J Hepatol. 2012;57(2):421–9.PubMedCrossRef Van Beers BE, Pastor CM, Hussain HK. Primovist, Eovist: what to expect? J Hepatol. 2012;57(2):421–9.PubMedCrossRef
3.
go back to reference Tamada T, Ito K, Yoshida K, Kanki A, Higaki A, Tanimoto D, Higashi H. Comparison of three different injection methods for arterial phase of Gd-EOB-DTPA enhanced MR imaging of the liver. Eur J Radiol. 2011;80(3):e284–8.PubMedCrossRef Tamada T, Ito K, Yoshida K, Kanki A, Higaki A, Tanimoto D, Higashi H. Comparison of three different injection methods for arterial phase of Gd-EOB-DTPA enhanced MR imaging of the liver. Eur J Radiol. 2011;80(3):e284–8.PubMedCrossRef
4.
go back to reference Choi Y, Huh J, Woo DC, Kim KW. Use of gadoxetate disodium for functional MRI based on its unique molecular mechanism. Br J Radiol. 2016;89(1058):20150666.PubMedPubMedCentralCrossRef Choi Y, Huh J, Woo DC, Kim KW. Use of gadoxetate disodium for functional MRI based on its unique molecular mechanism. Br J Radiol. 2016;89(1058):20150666.PubMedPubMedCentralCrossRef
5.
go back to reference Huh J, Kim KW, Kim J, Yu E. Pathology-MRI correlation of hepatocarcinogenesis: recent update. J Pathol Translat Med. 2015;49(3):218–29.CrossRef Huh J, Kim KW, Kim J, Yu E. Pathology-MRI correlation of hepatocarcinogenesis: recent update. J Pathol Translat Med. 2015;49(3):218–29.CrossRef
6.
go back to reference Sung YS, Park B, Choi Y, Lim HS, Woo DC, Kim KW, Kim JK. Dynamic contrast-enhanced MRI for oncology drug development. J Magn Reso Imaging. 2016;44(2):251–64.CrossRef Sung YS, Park B, Choi Y, Lim HS, Woo DC, Kim KW, Kim JK. Dynamic contrast-enhanced MRI for oncology drug development. J Magn Reso Imaging. 2016;44(2):251–64.CrossRef
7.
go back to reference Bae KE, Kim SY, Lee SS, Kim KW, Won HJ, Shin YM, Kim PN, Lee MG. Assessment of hepatic function with Gd-EOB-DTPA-enhanced hepatic MRI. Dig Dis (Basel, Switzerland). 2012;30(6):617–22.CrossRef Bae KE, Kim SY, Lee SS, Kim KW, Won HJ, Shin YM, Kim PN, Lee MG. Assessment of hepatic function with Gd-EOB-DTPA-enhanced hepatic MRI. Dig Dis (Basel, Switzerland). 2012;30(6):617–22.CrossRef
8.
go back to reference Chen YW, Tsai MY, Pan HB, Tseng HH, Hung YT, Chou CP. Gadoxetic acid-enhanced MRI and sonoelastography: non-invasive assessments of chemoprevention of liver fibrosis in thioacetamide-induced rats with Sho-Saiko-to. PLoS One. 2014;9(12):e114756.PubMedPubMedCentralCrossRef Chen YW, Tsai MY, Pan HB, Tseng HH, Hung YT, Chou CP. Gadoxetic acid-enhanced MRI and sonoelastography: non-invasive assessments of chemoprevention of liver fibrosis in thioacetamide-induced rats with Sho-Saiko-to. PLoS One. 2014;9(12):e114756.PubMedPubMedCentralCrossRef
9.
go back to reference Giraudeau C, Leporq B, Doblas S, Lagadec M, Pastor CM, Daire JL, Van Beers BE. Gadoxetate-enhanced MR imaging and compartmental modelling to assess hepatocyte bidirectional transport function in rats with advanced liver fibrosis. Eur Radiol. 2017;27(5):1804–11.PubMedCrossRef Giraudeau C, Leporq B, Doblas S, Lagadec M, Pastor CM, Daire JL, Van Beers BE. Gadoxetate-enhanced MR imaging and compartmental modelling to assess hepatocyte bidirectional transport function in rats with advanced liver fibrosis. Eur Radiol. 2017;27(5):1804–11.PubMedCrossRef
10.
go back to reference Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG. Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol. 2010;8(6):e1000412.PubMedPubMedCentralCrossRef Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG. Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol. 2010;8(6):e1000412.PubMedPubMedCentralCrossRef
11.
go back to reference Liedtke C, Luedde T, Sauerbruch T, Scholten D, Streetz K, Tacke F, Tolba R, Trautwein C, Trebicka J, Weiskirchen R. Experimental liver fibrosis research: update on animal models, legal issues and translational aspects. Fibrogenesis Tissue Repair. 2013;6(1):19.PubMedPubMedCentralCrossRef Liedtke C, Luedde T, Sauerbruch T, Scholten D, Streetz K, Tacke F, Tolba R, Trautwein C, Trebicka J, Weiskirchen R. Experimental liver fibrosis research: update on animal models, legal issues and translational aspects. Fibrogenesis Tissue Repair. 2013;6(1):19.PubMedPubMedCentralCrossRef
12.
go back to reference Kim YO, Popov Y, Schuppan D. Optimized Mouse Models for Liver Fibrosis. Methods Mol Biol (Clifton, NJ). 2017;1559:279–96.CrossRef Kim YO, Popov Y, Schuppan D. Optimized Mouse Models for Liver Fibrosis. Methods Mol Biol (Clifton, NJ). 2017;1559:279–96.CrossRef
13.
go back to reference Toyama T, Nakamura H, Harano Y, Yamauchi N, Morita A, Kirishima T, Minami M, Itoh Y, Okanoue T. PPARα ligands activate antioxidant enzymes and suppress hepatic fibrosis in rats. Biochem Biophys Res Commun. 2004;324(2):697–704.PubMedCrossRef Toyama T, Nakamura H, Harano Y, Yamauchi N, Morita A, Kirishima T, Minami M, Itoh Y, Okanoue T. PPARα ligands activate antioxidant enzymes and suppress hepatic fibrosis in rats. Biochem Biophys Res Commun. 2004;324(2):697–704.PubMedCrossRef
14.
go back to reference Feier D, Balassy C, Bastati N, Stift J, Badea R, Ba-Ssalamah A. Liver fibrosis: histopathologic and biochemical influences on diagnostic efficacy of hepatobiliary contrast-enhanced MR imaging in staging. Radiology. 2013;269(2):460–8.PubMedCrossRef Feier D, Balassy C, Bastati N, Stift J, Badea R, Ba-Ssalamah A. Liver fibrosis: histopathologic and biochemical influences on diagnostic efficacy of hepatobiliary contrast-enhanced MR imaging in staging. Radiology. 2013;269(2):460–8.PubMedCrossRef
15.
go back to reference Zhang W, Kong X, Wang ZJ, Luo S, Huang W, Zhang LJ. Dynamic contrast-enhanced magnetic resonance imaging with Gd-EOB-DTPA for the evaluation of liver fibrosis induced by carbon tetrachloride in rats. PLoS One. 2015;10(6):e0129621.PubMedPubMedCentralCrossRef Zhang W, Kong X, Wang ZJ, Luo S, Huang W, Zhang LJ. Dynamic contrast-enhanced magnetic resonance imaging with Gd-EOB-DTPA for the evaluation of liver fibrosis induced by carbon tetrachloride in rats. PLoS One. 2015;10(6):e0129621.PubMedPubMedCentralCrossRef
16.
go back to reference Bataller R, Gao B. Liver fibrosis in alcoholic liver disease. Semin Liver Dis. 2015;35(2):146–56.PubMedCrossRef Bataller R, Gao B. Liver fibrosis in alcoholic liver disease. Semin Liver Dis. 2015;35(2):146–56.PubMedCrossRef
17.
go back to reference Kang BK, Lee SS, Cheong H, Hong SM, Jang K, Lee MG. Shear wave elastography for assessment of steatohepatitis and hepatic fibrosis in rat models of non-alcoholic fatty liver disease. Ultrasound Med Biol. 2015;41(12):3205–15.PubMedCrossRef Kang BK, Lee SS, Cheong H, Hong SM, Jang K, Lee MG. Shear wave elastography for assessment of steatohepatitis and hepatic fibrosis in rat models of non-alcoholic fatty liver disease. Ultrasound Med Biol. 2015;41(12):3205–15.PubMedCrossRef
18.
go back to reference De Gasperi A, Mazza E, Prosperi M. Indocyanine green kinetics to assess liver function: ready for a clinical dynamic assessment in major liver surgery? World J Hepatol. 2016;8(7):355–67.PubMedPubMedCentralCrossRef De Gasperi A, Mazza E, Prosperi M. Indocyanine green kinetics to assess liver function: ready for a clinical dynamic assessment in major liver surgery? World J Hepatol. 2016;8(7):355–67.PubMedPubMedCentralCrossRef
19.
go back to reference Lee HB, Blaufox MD. Blood volume in the rat. J Nuclear Med. 1985;26(1):72–6. Lee HB, Blaufox MD. Blood volume in the rat. J Nuclear Med. 1985;26(1):72–6.
20.
go back to reference Mukaka MM. A guide to appropriate use of correlation coefficient in medical research. Malawi Med J. 2012;24(3):69–71.PubMedPubMedCentral Mukaka MM. A guide to appropriate use of correlation coefficient in medical research. Malawi Med J. 2012;24(3):69–71.PubMedPubMedCentral
21.
go back to reference Baguley BC, Holdaway KM, Thomsen LL, Zhuang L, Zwi LJ. Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine: evidence for a vascular mechanism. Eur J Cancer. 1991;27(4):482–7.PubMedCrossRef Baguley BC, Holdaway KM, Thomsen LL, Zhuang L, Zwi LJ. Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine: evidence for a vascular mechanism. Eur J Cancer. 1991;27(4):482–7.PubMedCrossRef
22.
go back to reference Muller A, Machnik F, Zimmermann T, Schubert H. Thioacetamide-induced cirrhosis-like liver lesions in rats--usefulness and reliability of this animal model. Exp Pathol. 1988;34(4):229–36.PubMedCrossRef Muller A, Machnik F, Zimmermann T, Schubert H. Thioacetamide-induced cirrhosis-like liver lesions in rats--usefulness and reliability of this animal model. Exp Pathol. 1988;34(4):229–36.PubMedCrossRef
23.
go back to reference de Graaf W, Hausler S, Heger M, van Ginhoven TM, van Cappellen G, Bennink RJ, Kullak-Ublick GA, Hesselmann R, van Gulik TM, Stieger B. Transporters involved in the hepatic uptake of (99m)Tc-mebrofenin and indocyanine green. J Hepatol. 2011;54(4):738–45.PubMedCrossRef de Graaf W, Hausler S, Heger M, van Ginhoven TM, van Cappellen G, Bennink RJ, Kullak-Ublick GA, Hesselmann R, van Gulik TM, Stieger B. Transporters involved in the hepatic uptake of (99m)Tc-mebrofenin and indocyanine green. J Hepatol. 2011;54(4):738–45.PubMedCrossRef
24.
go back to reference Tsuda N, Matsui O. Cirrhotic rat liver: reference to transporter activity and morphologic changes in bile canaliculi--gadoxetic acid-enhanced MR imaging. Radiology. 2010;256(3):767–73.PubMedCrossRef Tsuda N, Matsui O. Cirrhotic rat liver: reference to transporter activity and morphologic changes in bile canaliculi--gadoxetic acid-enhanced MR imaging. Radiology. 2010;256(3):767–73.PubMedCrossRef
25.
go back to reference Tajima T, Takao H, Akai H, Kiryu S, Imamura H, Watanabe Y, Shibahara J, Kokudo N, Akahane M, Ohtomo K. Relationship between liver function and liver signal intensity in hepatobiliary phase of gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging. J Comput Assist Tomogr. 2010;34(3):362–6.PubMedCrossRef Tajima T, Takao H, Akai H, Kiryu S, Imamura H, Watanabe Y, Shibahara J, Kokudo N, Akahane M, Ohtomo K. Relationship between liver function and liver signal intensity in hepatobiliary phase of gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging. J Comput Assist Tomogr. 2010;34(3):362–6.PubMedCrossRef
26.
go back to reference Yamada A, Hara T, Li F, Fujinaga Y, Ueda K, Kadoya M, Doi K. Quantitative evaluation of liver function with use of gadoxetate disodium-enhanced MR imaging. Radiology. 2011;260(3):727–33.PubMedCrossRef Yamada A, Hara T, Li F, Fujinaga Y, Ueda K, Kadoya M, Doi K. Quantitative evaluation of liver function with use of gadoxetate disodium-enhanced MR imaging. Radiology. 2011;260(3):727–33.PubMedCrossRef
27.
go back to reference Katsube T, Okada M, Kumano S, Hori M, Imaoka I, Ishii K, Kudo M, Kitagaki H, Murakami T. Estimation of liver function using T1 mapping on Gd-EOB-DTPA-enhanced magnetic resonance imaging. Investig Radiol. 2011;46(4):277–83.CrossRef Katsube T, Okada M, Kumano S, Hori M, Imaoka I, Ishii K, Kudo M, Kitagaki H, Murakami T. Estimation of liver function using T1 mapping on Gd-EOB-DTPA-enhanced magnetic resonance imaging. Investig Radiol. 2011;46(4):277–83.CrossRef
28.
go back to reference Nilsson H, Blomqvist L, Douglas L, Nordell A, Janczewska I, Naslund E, Jonas E. Gd-EOB-DTPA-enhanced MRI for the assessment of liver function and volume in liver cirrhosis. Br J Radiol. 2013;86(1026):20120653.PubMedPubMedCentralCrossRef Nilsson H, Blomqvist L, Douglas L, Nordell A, Janczewska I, Naslund E, Jonas E. Gd-EOB-DTPA-enhanced MRI for the assessment of liver function and volume in liver cirrhosis. Br J Radiol. 2013;86(1026):20120653.PubMedPubMedCentralCrossRef
29.
go back to reference Motosugi U, Ichikawa T, Sou H, Sano K, Tominaga L, Kitamura T, Araki T. Liver parenchymal enhancement of hepatocyte-phase images in Gd-EOB-DTPA-enhanced MR imaging: which biological markers of the liver function affect the enhancement? J Magn Reson Imaging. 2009;30(5):1042–6.PubMedCrossRef Motosugi U, Ichikawa T, Sou H, Sano K, Tominaga L, Kitamura T, Araki T. Liver parenchymal enhancement of hepatocyte-phase images in Gd-EOB-DTPA-enhanced MR imaging: which biological markers of the liver function affect the enhancement? J Magn Reson Imaging. 2009;30(5):1042–6.PubMedCrossRef
30.
go back to reference Ryeom HK, Kim SH, Kim JY, Kim HJ, Lee JM, Chang YM, Kim YS, Kang DS. Quantitative evaluation of liver function with MRI using Gd-EOB-DTPA. Korean J Radiol. 2004;5(4):231–9.PubMedPubMedCentralCrossRef Ryeom HK, Kim SH, Kim JY, Kim HJ, Lee JM, Chang YM, Kim YS, Kang DS. Quantitative evaluation of liver function with MRI using Gd-EOB-DTPA. Korean J Radiol. 2004;5(4):231–9.PubMedPubMedCentralCrossRef
31.
go back to reference Nilsson H, Blomqvist L, Douglas L, Nordell A, Jacobsson H, Hagen K, Bergquist A, Jonas E. Dynamic gadoxetate-enhanced MRI for the assessment of total and segmental liver function and volume in primary sclerosing cholangitis. J Magn Reson Imaging. 2014;39(4):879–86.PubMedCrossRef Nilsson H, Blomqvist L, Douglas L, Nordell A, Jacobsson H, Hagen K, Bergquist A, Jonas E. Dynamic gadoxetate-enhanced MRI for the assessment of total and segmental liver function and volume in primary sclerosing cholangitis. J Magn Reson Imaging. 2014;39(4):879–86.PubMedCrossRef
32.
go back to reference Talakic E, Steiner J, Kalmar P, Lutfi A, Quehenberger F, Reiter U, Fuchsjager M, Schollnast H. Gd-EOB-DTPA enhanced MRI of the liver: correlation of relative hepatic enhancement, relative renal enhancement, and liver to kidneys enhancement ratio with serum hepatic enzyme levels and eGFR. Eur J Radiol. 2014;83(4):607–11.PubMedCrossRef Talakic E, Steiner J, Kalmar P, Lutfi A, Quehenberger F, Reiter U, Fuchsjager M, Schollnast H. Gd-EOB-DTPA enhanced MRI of the liver: correlation of relative hepatic enhancement, relative renal enhancement, and liver to kidneys enhancement ratio with serum hepatic enzyme levels and eGFR. Eur J Radiol. 2014;83(4):607–11.PubMedCrossRef
Metadata
Title
Gadoxetate-enhanced dynamic contrast-enhanced MRI for evaluation of liver function and liver fibrosis in preclinical trials
Authors
Jimi Huh
Su Jung Ham
Young Chul Cho
Bumwoo Park
Bohyun Kim
Chul-Woong Woo
Yoonseok Choi
Dong-Cheol Woo
Kyung Won Kim
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Medical Imaging / Issue 1/2019
Electronic ISSN: 1471-2342
DOI
https://doi.org/10.1186/s12880-019-0378-5

Other articles of this Issue 1/2019

BMC Medical Imaging 1/2019 Go to the issue